Cargando…

Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review

Dipeptidyl peptidase-4 inhibitors (DPP4Is) were introduced into the management of type 2 diabetes mellitus (T2DM) as they are insulinotropic and have no inherent risk of hypoglycemia and no effect on body weight. Currently, 11 drugs in this class are available for the management of diabetes. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridhar, GR, Pandit, Kaushik, Warrier, Sona, Birla, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291938/
https://www.ncbi.nlm.nih.gov/pubmed/37378205
http://dx.doi.org/10.7759/cureus.39204
_version_ 1785062784075038720
author Sridhar, GR
Pandit, Kaushik
Warrier, Sona
Birla, Ashish
author_facet Sridhar, GR
Pandit, Kaushik
Warrier, Sona
Birla, Ashish
author_sort Sridhar, GR
collection PubMed
description Dipeptidyl peptidase-4 inhibitors (DPP4Is) were introduced into the management of type 2 diabetes mellitus (T2DM) as they are insulinotropic and have no inherent risk of hypoglycemia and no effect on body weight. Currently, 11 drugs in this class are available for the management of diabetes. Although they have a similar mechanism of action, they differ from one other in their binding mechanisms, which influences their therapeutic and pharmacological profiles. Vildagliptin's overall safety and tolerability profile was comparable to placebo throughout clinical studies, and real-world data in a large group of T2DM patients corroborated this finding. Therefore, DPP4Is like vildagliptin is a secure alternative for treating patients with T2DM. Vildagliptin treatment given as a once-daily (QD) 100 mg sustained release (SR) formulation fits the criteria of adherence and compliance. This SR formulation, given once daily has the potential to provide glycemic control like the vildagliptin 50 mg twice-daily (BD) formulation. This comprehensive review discusses the journey of vildagliptin as 50 mg BD therapy as well as 100 mg SR QD therapy.
format Online
Article
Text
id pubmed-10291938
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102919382023-06-27 Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review Sridhar, GR Pandit, Kaushik Warrier, Sona Birla, Ashish Cureus Endocrinology/Diabetes/Metabolism Dipeptidyl peptidase-4 inhibitors (DPP4Is) were introduced into the management of type 2 diabetes mellitus (T2DM) as they are insulinotropic and have no inherent risk of hypoglycemia and no effect on body weight. Currently, 11 drugs in this class are available for the management of diabetes. Although they have a similar mechanism of action, they differ from one other in their binding mechanisms, which influences their therapeutic and pharmacological profiles. Vildagliptin's overall safety and tolerability profile was comparable to placebo throughout clinical studies, and real-world data in a large group of T2DM patients corroborated this finding. Therefore, DPP4Is like vildagliptin is a secure alternative for treating patients with T2DM. Vildagliptin treatment given as a once-daily (QD) 100 mg sustained release (SR) formulation fits the criteria of adherence and compliance. This SR formulation, given once daily has the potential to provide glycemic control like the vildagliptin 50 mg twice-daily (BD) formulation. This comprehensive review discusses the journey of vildagliptin as 50 mg BD therapy as well as 100 mg SR QD therapy. Cureus 2023-05-18 /pmc/articles/PMC10291938/ /pubmed/37378205 http://dx.doi.org/10.7759/cureus.39204 Text en Copyright © 2023, Sridhar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Sridhar, GR
Pandit, Kaushik
Warrier, Sona
Birla, Ashish
Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
title Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
title_full Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
title_fullStr Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
title_full_unstemmed Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
title_short Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
title_sort sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291938/
https://www.ncbi.nlm.nih.gov/pubmed/37378205
http://dx.doi.org/10.7759/cureus.39204
work_keys_str_mv AT sridhargr sustainedreleasevildagliptin100mgintype2diabetesmellitusareview
AT panditkaushik sustainedreleasevildagliptin100mgintype2diabetesmellitusareview
AT warriersona sustainedreleasevildagliptin100mgintype2diabetesmellitusareview
AT birlaashish sustainedreleasevildagliptin100mgintype2diabetesmellitusareview